Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 May 17];7(2):s196. Available from: https://skin.dermsquared.com/skin/article/view/2037